Rafina’s Subsidiary C-Pharm Ltd Revenues for First Quarter 2021 $1.7 Million

Nicosia, Cyprus – (NewMediaWire) – May 25, 2021 – Rafina Innovations Inc. (OTC PINK:
VICA), a Medical and Pharmaceutical development company, is pleased to
announce C-Pharm’s 1st Quarter -31 March, 2021- revenues for 2021 are $1.7
Million US dollars.

Rafina’s CEO stated, “Over a year into the pandemic,
C-Pharm managed to increase its revenues from $700,000 within the first quarter
of 2020 to $1.7 million in the first quarter of 2021, by acquiring new business
strategies, expanding in new territories and creating new opportunities during
difficult times. We have significantly increased our distribution and sale in
pharmaceutical products throughout Europe. The next goal is to expand further
into the Europe – Asia territories.”

C-Pharm’s unique business model allows Rafina to introduce its
other suite of products to existing C-Pharm customers and industries. This is a
massive opportunity for Rafina Innovations, Inc. to expand its businesses and
create a global hub for medical supplies in addition to PPE and other related
products and companies. 

About Rafina Innovations Inc.

Rafina Innovations Inc. is a development capital investment
opportunity in the high growth / high margin prosthetics, orthotics,
rehabilitation, and diabetes markets. It benefits from a market leading footing
from which to expand and seeks to invest in a synergistic business model of Rafina
Innovations Clinics and new technology development, with an out-licensing
model. The company has a strong pipeline of near-market to research-stage
technologies, developed by a team that includes world-renowned experts in their
field, each committed to the company on an on-going basis.

The Rafina Innovations Clinics can be early adopters of the
technologies and provide the springboard for further innovation, as well as
opportunities for lower-cost clinical trials. This synergistic model will allow
the company to sustain high margins and accelerate revenue growth as both the
number of clinics and products grow.

About C-Pharm Ltd

C-PHARM is a leading distributor for medical supplies and
equipment striving to supply the world with everything needed. High Standards,
Affordable Packages, Private Agreements, top quality and support are some of
the words that define us, as a Company.

Safe Harbor Statement: Safe harbor from liability established by
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements generally can be identified by phrases such as VICA, Rafina
Innovations or its management “believes,” “expects,”
“anticipates,” “foresees,” “forecasts,”
“estimates” or other words or phrases of similar import. Similarly,
statements herein that describe the Company’s business strategy, outlook,
objectives, plans, intentions, or goals also are forward- looking statements.
All such forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially from those
in forward-looking statements.

Please visit: 

https:

https:www.vicahub.com/ 

https://c-pharm.org/

Forward Looking Statements 

This
press release contains forward-looking statements. Forward-looking statements
are subject to risks, uncertainties and assumptions and are identified by words
such as “expects”, “intends”, “estimates”,
“projects”, “anticipates”, “believes”,
“could”, and other similar words. All statements addressing product
performance, events, or developments that the Company expects or anticipates
will occur in the future are forward-looking statements, including but not
limited to future developments in the areas of athletic shoes and the
information and performance of the Company’s technology in such applications.
Because the statements are forward-looking, they should be evaluated
considering important risk factors and uncertainties, some of which are
described in the Company’s Quarterly, Annual and Current Reports filed with the
OTC. Should one or more of these risks or uncertainties materialize or should
any of the Company’s underlying assumptions prove correct, actual results may
vary materially from those currently anticipated. In addition, undue reliance
should not be placed on Company’s forward-looking statements. In particular,
the Company has acquired its first operational Prosthetics & Orthotics
(P&O) clinic and is continuing development efforts for its other biomedical
technologies, including a “smart insole” and its Flexisense™ sensing
technology with several potential applications. There is no assurance that the
Company will be successful in its ongoing expansion and development efforts, or
that it will find suitable commercialization partners for its technologies.
Except as required by law, Rafina Innovations Inc. disclaims any obligation to
update or publicly announce any revisions to any of the forward-looking
statements contained in this press release. There can be no assurance that such
statements will prove to be accurate and actual results and future events could
differ materially from those anticipated in such statements. No stock exchange,
securities commission or other regulatory body has reviewed nor accepts
responsibility for the adequacy or accuracy of this release. Investors are
advised to carefully review the reports and documents that Rafina Innovations
files from time to time with the OTC, including its Annual, Quarterly and
Current Reports.

For
Investors Relations:

Website: www.vicahub.com

www.rafina-innovations.com

Email:
info@rafinainnovations.com

SOURCE:
Rafina Innovations Inc.